Anti-osteoporosis Effect of 5-Bromo-2-(4-chlorobenzoyl)-(Z)-3-(2-cyano-3-hydroxybut-2-enonyl)aminobenzo[b]furan: a Novel Selective Estrogen Receptor Modulator

Journal of Pharmacological Sciences - Tập 116 - Trang 214-220 - 2011
Ryo Fukuyama1, Akio Shimokawa2, Yasushi Kodama3, Mitsugu Fujita1, Yoshitaka Ohishi4,5, Yuko Ando4, Masao Koida6, Hiromichi Nakamuta1
1Laboratory of Pharmacology, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan
2Department of Pharmacy, National Hospital Organization Kanmon Medical Center, 1-1 Chofusotoura-cho, Shimonoseki, Yamaguchi 752-8510, Japan
3Laboratory of Molecular and Cellular Pharmacology, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan
4School of Pharmaceutical Sciences, Mukogawa Women’s University, Koshien Kyubancho, Nishinomiya, Hyogo 663-8179, Japan
5School of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kodo, Kyotanabe, Kyoto 610-0395, Japan
6Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hiraka, Osaka 573-0101, Japan

Tài liệu tham khảo

1 Loose DS, Stancel GM. Estrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutic. 8th ed. New York: Mcgraw-Hill; 2006. p. 1541–1572.

2 Rexrode KM. Emerging risk factors in women. Stroke. 2010;41:S9–S11.

10.1111/j.1749-6632.2009.04982.x

4 Lindsay R, Cosman F. Osteoporosis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw-Hill; 2001. p. 2226–2237.

10.1016/S0140-6736(06)68891-0

6 Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473–1480.

7 Colditz GA, Hankinson SE, Hunter DJ, Willett WG, Manson JE, Stampeer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–1593.

10.1073/pnas.94.25.14105

9 Taylor HS. Designing the ideal selective estrogen receptor modulator – an achievable goal? Menopause. 2009;16:609–615.

10.1254/jphs.FM0070218

10.1001/jama.282.7.637

12 Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Sat. 2005;28:721–730.

10.1016/j.bmcl.2006.08.064

14 Tabuchi Y, Ando Y, Kanemura I, Ohishi T, Koida M, Fukuyama R, et al. Preparation of novel (Z)-4-ylidenebenzo[<I>b</I>]furo[3,2-d][1,3]oxazines and their biological activity. Bioorg Med Chem. 2009;17:3959&ndash;3967.

10.1016/0960-0760(92)90204-V

16 Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175&ndash;179.

10.1073/pnas.95.7.3597

10.1073/pnas.87.18.7260

10.1016/0169-6009(91)90124-I

10.1254/jjp.79.379

21 Atkinson PJ. Variation in trabecular structure of vertebrae with age. Calcif Tissue Res. 1967;1:24&ndash;32.

22 Rodin A, Murby B, Smith MA, Caleffi M, Fentiman I, Chapman MG, et al. Premenopausal bone loss in the lumbar spine and neck of femur: a study of 225 Caucasian women. Bone. 1990;11:1&ndash;5.

10.1016/8756-3282(93)90081-K

10.1016/j.cell.2007.07.025

10.1016/j.yexcr.2009.01.014

Thông tin
Thông tin xuất bản

Journal of Pharmacological Sciences

Tập 116

214-220

Thông tin tác giả